Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 1, 2004, Pages 56-62

  Okabe, Satoshi ^a   Arai, Takehiro ^a   Yamashita, Hironori ^a   Sugihara, Kenichi ^a   Sasaki, Tsuneo ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Biochemical modulation; cis diamminedichloroplatinum; Colorectal carcinoma; dl leucovorin

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; MALE; OUTPATIENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VOMITING;

EID: 1642480126     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03267.x     Document Type: Article

References (29)

1. Scheithauer W, Rosen H, Schiessel R et al. Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil and leucovorin. Cancer 1991; 67: 1294-8.
2. Carlosson G, Graf W, Gustavsson BG, Spears PC. Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. Eur. J. Cancer 1990; 26: 874-6.
3. Kemeny N, Israel K, Niedzwiecki D et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J. Clin. Oncol. 1990; 8: 313-8.
4. ACCMAP. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project [see comments]. J. Clin. Oncol. 1992; 10: 896-903.
5. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl. J. Med. 2000; 343: 905-14.
6. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7.
7. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J. Clin. Oncol. 2002; 20: 1192-202.
8. Moertel CG, Fleming TR, MacDonald JS, Haller DG. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 1990; 322: 352-8.
9. Okabe S, Arai T, Maruyama S et al. [A randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP 5-FU and dl-leucovorin for colorectal cancer]. Gan Kagaku Ryoho 1997; 24: 849-54 (in Japanese).
10. Scheithauer W, Depisch D, Kornek G et al. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer 1994; 73: 1562-8.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
12. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989; 63: 1026-30.
13. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989; 63: 1036-44.
14. Shirasaka T, Shimamoto Y, Ohshimo H, Kimura A, Fukushima M. [Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil]. Gan Kagaku Ryoho 1991; 18: 403-9 (in Japanese).
15. Crum ED. Effect of cisplatin upon expression of in vivo immune tumor resistance. Cancer Immunol. Immunother. 1993; 36: 18-24.
16. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators [see comments]. J. Clin. Oncol. 1999; 17: 1356-63.
17. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) [see comments]. J. Clin. Oncol. 1999; 17: 1349-55.
18. Ahn JB, Shim KY, Jeung HC et al. Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. Cancer Lett. 2001; 167: 215-24.
19. Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J. Clin. Oncol. 1997; 15: 2432-41.
20. Pitot HC, Goldberg RM. Future directions in adjuvant therapy for stage III colon carcinoma. Oncology 2001; 15: 31-6.
21. Porschen R, Bermann A, Loffler T et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J. Clin. Oncol. 2001; 19: 1787-94.
22. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. 1999; 17: 3553-9.
23. Bleeker WA, Mulder NH, Hermans J, Otter R, Plukker JT. The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group. Ann. Oncol. 2000; 11: 547-52.
24. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol. 1993; 11: 1879-87.
25. Moertel CG. Chemotherapy for colorectal cancer. N. Engl. J. Med. 1994; 330: 1136-42.
26. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001; 19: 2576-82.
27. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345-50.
28. Harris JE, Ryan L, Hoover HC Jr et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 2000; 18: 148-57.
29. Baars A, Claessen AM, Wagstaff J et al. A phase n study of active specific immunotherapy and 5-FU/leucovorin as adjuvant therapy for stage III colon carcinoma. Br. J. Cancer 2002; 86: 1230-4.